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Summary:
Hemorrhagic cystitis (HC) is a common toxicity of pre-
parative regimens for bone marrow transplantation
(BMT). Severe HC often requires prolonged and
expensive hospitalization, and occasionally can result in
death. To investigate the risk factors for severe HC, we
conducted a retrospective study among 1908 patients
who received BMTs at the University of Minnesota dur-
ing 1974 to 1993. A previous report from our institution
reported on 977 of these patients. We identified all
patients with genitourinary complication within 100
days post-BMT from the BMT database. Medical charts
for these patients were reviewed to determine whether
the patient had HC and also the grade of HC. A total
of 208 HC cases were identified during the study period.
Of them, 92 patients had severe HC, an incidence of 5%
(95% CI = 4–6%). We found that grade II–IV graft-
versus-host disease (RR = 2.56; 95% CI = 1.43–4.56),
use of busulfan (RR = 2.69; 95% CI = 1.35–5.35), and
age at transplant (RR = 2.20; 95% CI = 1.27–3.81, for
age of 10–30 compared to age of 0–9) were related to
an increased risk of HC. In contrast, transplant year
was inversely associated with the risk of HC (trend test,
P , 0.01). We did not find any significant difference in
HC with the use of prophylactic Mesna.
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Outcome after bone marrow transplantation (BMT) has
improved over the past 20 years,1 but preparative regimen-
related toxicities (RRT) remain a major limitation to further
progress. Hemorrhagic cystitis (HC) is a common RRT.2 In
the BMT setting, HC occurring in the early post-transplant
period is more frequently associated with the use of cyclo-
phosphamide (CY), while late occurring HC frequently
results from viral infections (eg BK virus, adenovirus type
II).3–8 CY has been widely used for conditioning patients
undergoing BMT. The drug is hydroxylated in the liver,
generating 4 hydroxy-CY, phosphoramide mustard, and
acrolein. Excreted in the urine, acrolein can cause edema,
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inflammation, ulceration, hemorrhage, and necrosis of the
urothelium within a few hours.9 The diagnosis of HC is
usually made when hematuria occurs in the absence of uri-
nary tract bacterial infection or generalized hemorrhagic
diathesis.10 Clinical presentation of HC varies from mild
limited hematuria and/or dysuria to uncontrollable gross
bleeding, urinary obstruction, and acute renal failure.
Reported incidence rates of HC post-BMT ranged from 7%
to 52%.11,12 This rather wide range of estimate is primarily
attributable to the disparate definitions of HC used in the
literature, ranging from six11 to greater than 10013 red blood
cells per high power field (RBC/hpf) in the urinalysis. HC
is graded as mild, moderate or severe according to degree
of pain and hematuria. Although there is an inconsistency
in definition of mild and moderate HC, severe cystitis usu-
ally includes presence of gross hematuria with clots and
occurrence of clinical complications. Severe cystitis has
been reported to occur in about 5% of BMT patients
(ranging from 0%9 to 18%).10,11 It can be extremely painful
and debilitating, requiring prolonged and expensive hospi-
talizations, and can contribute to death.14 Numerous
therapeutic approaches have been tried to control pain and
bleeding but often without success.15–25
Because of the severity of HC and difficulty in its treat-
ment, maximal efforts have been made to prevent this
complication. Sodium 6 mercaptoethane sulfonate
(Mesna) is a sulfhydryl compound that binds to acrolein,
and therefore prevents urothelial damage. Mesna was
prophylactically initiated as part of the preparative regi-
men for BMT at the University of Minnesota in 1989. We
conducted a retrospective study to examine the major risk
factors for HC and the impact of prophylactic Mesna.
Because of clinical relevance and consistency in the diag-
nosis between and within institutions, this study focused
on severe HC.
Patients and methods
Information on all patients receiving BMT at the University
of Minnesota, including sex, age, diagnosis, remission
status, conditioning therapy, graft-versus-host disease
(GVHD) prophylaxis, and complications of the transplants,
is prospectively collected by the BMT database. Patients
with any genitourinary complication were first identified
from the database files. Using database reports and chart
review, HC was graded as mild, moderate, or severe, as
previously reported:14 mild HC was defined as sustained
(>7 days) microscopic hematuria; moderate HC was
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36 defined by the presence of clots, dysuria or gross hematuria;
and severe HC by the presence of complications such as
urinary obstruction, renal failure, uncontrollable bleeding
requiring bladder irrigation, topical instillations (eg alum
and formalin), cauterization, or surgical intervention. In
patients with intermittent or recurrent symptoms, the date
of onset of HC was defined as the first day of HC symptoms
or laboratory evidence appearing post-initiation of the con-
ditioning therapy. The worst clinical presentation was con-
sidered as the grade of HC. When severe cystitis was ident-
ified, a complete chart review was conducted to gather
information on clinical course, interventions, complications
and sequelae of the HC. Since availability of data on patient
follow-up after day 100 post-BMT depends on communi-
cation with the primary physician and on the frequency of
the patient visits, only HCs that occurred within 100 days
post-BMT were included in this analysis. Data on HC after
second transplant were analyzed separately. During the 1
year period (1989–1990) when Mesna was being incorpor-
ated into the preparative regimen protocols, patients receiv-
ing CY as part of the preparative regimen for BMT had
different methods of urinary prophylaxis. To define whether
the patients received Mesna, intravenous hyper-hydration
(IVH), or continuous bladder irrigation (CBI), medical
charts of all patients transplanted during that interval
were reviewed.
Prophylaxis for GVHD included cyclosporin A (CsA),
methotrexate (MTX), anti-thymocyte globulin (ATG), ster-
oids, elutriation or other forms of T cell depletion. Con-
ditioning therapy used busulfan, CY, or other chemotherapy
alone or combined with total body irradiation (TBI) or total
lymphoid irradiation (TLI). CY doses ranged from 20 to
240 mg/kg, administered as a 2-h infusion, over 1 to 4 days,
with a maximum of 60 mg/kg/day. Hydration with 3–4
l/m2/day started 6–12 h before the first CY infusion and
finished 24 h after the last dose. Patients voided every 1–
2 h during hydration and furosemide was given as needed
to maintain adequate diuresis. Heme dipstick testing was
conducted at the bedside two to three times a day for the
initial hospitalization. If heme-positive, the urine was sent
for microscopic analysis and culture; some heme-positive
samples were also sent for electron microscopy to assess
for presence of viral particles. Urinalysis and urine cultures
were performed at least weekly during hospitalization, and
then, at every hospital visit until day 100. Positive results
from urine cultures were entered into the database.
Since 1990 all patients receiving CY at doses greater
than 60 mg/kg also received Mesna at equal total dose,
divided 15 min before and 3, 6, 9 and 12 h after each dose.
A few patients received Mesna as an intravenous continu-
ous infusion over 24 h after each dose of CY. The treatment
of HC consisted of intravenous hydration and platelet sup-
port. Renal and pelvic ultrasound were performed if urinary
obstruction was suspected. When clinically indicated,
patients were catheterized and the bladder continuously irri-
gated at 3–5 l/h, titrated to keep a pink outflow. If the bleed-
ing was not controlled, cystoscopy with clot removal and
fulguration of the bleeding sites was performed. Other top-
ical therapies included prostaglandins, formalin, alum, ami-
nocaproic acid (amicar) and glutamine.
Statistical analysis
The incidence of HC from initiation of conditioning therapy
to day 100 post-BMT was calculated by Kaplan–Meier esti-
mation, censoring at last follow-up, death, or second trans-
plant. Univariate comparisons were performed using Man-
tel–Cox log-rank test, and Tarone’s test for trend. Factors
examined in the univariate analysis included sex, transplant
type, year of transplant, age, underlying diagnosis, number
of remissions, use and dose of CY, use of busulfan, radi-
ation, presence of advanced GVHD (grade II–IV), and posi-
tive urine cultures. The Cox proportional hazard model was
applied in the multiple regression analysis. The incidence
of severe HC in patients with positive urine cultures was
calculated by Kaplan–Meier estimation. To assess the inci-
dence of late HC, additional censoring occurred for onset
of HC prior to day 60. Late HC is defined as onset of HC
between days 60 and 100 post-BMT.
Results
From 1974 to 1993, 1908 patients received BMT at the
University of Minnesota. Patient characteristics and their
association with severe HC are shown in Table 1.
Forty-one percent were female and 59% male. Half of
the patients were children (<19 years), most of them
younger than 9 years of age. Forty-five percent of the
patients were within the second to fourth decades of life
and only 4% were 50 years old or older. Most patients
received BMT to treat underlying malignancies: 44% acute
leukemia/myelodysplastic syndrome (MDS), 20% chronic
myelogenous leukemia (CML), and 21% other malig-
nancies. Other underlying diagnoses were severe aplastic
anemia (SAA), immunodeficiencies (ID), and metabolic
disorders (MD), accounting for 16% of all patients. Fifty-
one percent of patients had allogeneic transplants from
related donors (primarily matched sibling donors). Fourteen
percent of patients received allogeneic transplants from
unrelated donors. The remaining 35% of patients received
autologous transplants. Fifteen syngeneic transplants were
analyzed as autologous transplants. Sixty-one percent of
patients received CY as part of the conditioning therapy in
doses ,150 mg/kg; 27% had a total dose >150 mg/kg, and
10% did not receive CY. Within the CY users, 58%
received Mesna. Conditioning therapy also included radi-
ation in 81% of the patients, and busulfan in 10%. Fifty-
two percent of patients receiving allogeneic transplants
developed significant GVHD (grade II–IV).
HC was diagnosed in 208 patients. In 92 cases HC was
severe, an incidence of 5% (95% CI, 4–6%). The median
onset of HC was 30 days post conditioning therapy, ranging
from 3 to 98, with a mean of 35.6 days. Over the past two
decades the overall incidence of HC decreased from 30%
(95% CI, 18–42%) to 8% (95% CI, 6–10%) and the inci-
dence of severe cystitis decreased from 15% (95% CI, 5–
25%) to 4% (95% CI, 2–6%). The decline in the incidence
of HC was most evident in the early 1980s, before Mesna
was introduced into BMT practice at our institution (1989–
1990). The incidence of severe HC according to the type
of transplant (autologous, related or unrelated donor) is
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Table 1 Patient characteristics and risk factors associated with severe hemorrhagic cystitis
No. patients (%) Incidence of s.e. P
(n = 1908) severe HC (%)
Sex
Female 785 41.1 5 0.8 0.79
Male 1123 58.8 5 0.7
Transplant type
Autologous 660 34.6 3 0.7 0.01
Allo-related 981 51.4 6 0.8
Allo-unrelated 267 14.0 6 1.6
Age (years)
0–9 581 30.5 4 0.8 0.004
10–19 398 20.8 9 1.5
20–29 286 15.0 6 1.5
30–39 333 17.5 3 1.0
40–49 230 12.0 4 1.4
.50 80 4.2 3 2.1
Malignancy
No 300 15.7 8 1.6 0.01
Yes 1608 84.3 5 0.5
Number of remissions
0–2 1488 92.5 5 0.6 0.7
.2 113 7.0 4 1.9
Data not available 7 0.5
Underlying diagnosis
SAA/MD/ID 300 15.7 8 1.6 0.06
Acute leukemias/MDS 838 43.9 4 0.7
CML 375 19.7 6 1.3
Other malignancies 395 20.7 4 1.1
Cyclophosphamide
None 183 9.6 3 1.3 0.23
,150 mg/kg 1197 61.1 5 0.7
.150 mg/kg 528 26.8 6 1.1
Mesna (CY users only)
No 725 42.8 4 0.8 0.10
Yes 1000 58.0 6 0.8
Busulfan
No 1714 89.8 5 1.2 0.77
Yes 194 10.2 5 0.6
Radiation
No 363 19.0 5 1.2 0.77
Yes 1545 18.0 5 0.6
GVHD grade II–IV (allogeneic BMT only)
No 676 48.1 5 0.7 0.002
Yes 572 51.9 7 1.8
shown in Table 1. All types of transplants had a higher
incidence of severe HC when they were first introduced
into our medical practice. An incidence of severe HC as
high as 23% in the earlier years, progressively decreased
with all types of transplant to approximately 4% (related,
P = 0.05; unrelated donor, P = 0.03; autologous, P = 0.33).
Factors associated with a significantly elevated risk of
severe HC from univariate analysis were: age, type of trans-
plant, underlying disease, use of busulfan, and GVHD
grade II–IV (Table 1). Results from the multiple regression
analysis, using the model that best fitted the data, are shown
in Table 2. Independent risk factors for the development of
severe HC were GVHD grade II–IV (RR 2.56; 95% CI,
1.43–4.56), the use of busulfan (RR 2.69; 95% CI, 0.35–
5.35), and age at BMT (10–30 years old) compared to age
0–9 (RR 2.20; 95% CI, 0.27–3.81). Transplant year was
inversely related to risk of HC (trend test, P , 0.01). The
use of Mesna did not significantly influence occurrence of
severe HC (RR = 1.2, 95% CI, 0.5–3.2).
Positive urine culture data are shown in Table 3. Urine
culture was positive for adenovirus in 41 patients, who had
the highest incidence of severe HC, 29%, compared to 5%
for patients without positive adenovirus culture (P , 0.01).
Patients with positive urine cultures for cytomegalovirus
and bacteria also had a higher incidence of severe HC, 9%
(P , 0.01) and 6% (P = 0.03), respectively. There were
very few late events (six events after day 60); however,
later onset HC was associated with positive virus identifi-
cation.
One hundred and eleven patients received a second BMT
at day 28 to 3634 days, mean 535 days after the first trans-
plant. Mild or moderate HC was diagnosed in three patients
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after the first transplant, 15 patients after the second BMT,
and only one patient developed HC after both transplants.
No severe HC was diagnosed.
Two subgroups of patients were individually reviewed:
four patients with Down’s syndrome received BMT and
none of them developed HC. Among 12 patients trans-
planted for adrenoleukodystrophy (ALD) seven developed
HC, five of them severe.
Most patients were treated with continuous bladder irri-
gation (70%) or cystoscopy with clot evacuation and
fulguration of the bleeding sites (38%). Other treatments
were instillation of alum (14%) or formalin (7%), systemic
amicar (23%), prostaglandins (7%), and estrogens (2%).
Most patients received a combination of treatment
modalities. The complications of the severe cystitis within
Table 2 Risk factors for the development of severe hemorrhagic cys-
titis. Multiple regression analysis
Risk factors RR 95% CI P
Transplant type
Autologous 1.00
Allo-related 1.24 0.69–2.22 0.48
Allo-unrelated 1.52 0.72–3.23 0.28
Age (years)
0–9 1.00
10–30 2.20 1.27–3.81 0.05
.30 1.23 0.63–2.40 0.54
Cyclophosphamide
None 1.00
,150 mg/kg 1.54 0.60–3.98 0.37
.150 mg/kg 1.42 0.52–3.89 0.48
Trend testa 0.59
Busulfan
No 1.00
Yes 2.69 1.35–5.35 0.005
GVHD grade II–IV
No 1.00
Yes 2.56 1.43–4.56 0.002
Transplant year
1974–78 1.00
1979–82 0.48 0.20–1.16 0.10
1983–88 0.36 0.16–0.80 0.01
1989–90 0.25 0.09–0.63 0.04
1991–93 0.24 0.10–0.60 0.02
aTrend test, ¿0.01.
Table 3 Incidence of severe HC in patients with positive urine cultures
Urine culture No. patients (%) Incidence of s.e. P
result (n = 1908) severe HC (%)
Adenovirus
No 1867 97.9 5 0.5 ¿0.0001
Yes 41 2.1 29 7.0
Cytomegalovirus
No 1659 86.9 5 0.5 0.006
Yes 249 13.1 9 1.8
Bacteria
No 1017 53.3 4 0.6 0.03
Yes 891 46.7 6 0.8
100 days post-BMT were urinary obstruction (21%), acute
renal failure (21%) with need of dialysis in half of the
cases, hydronephrosis (10%), and death in five patients
(5%) (Table 4).
Discussion
Our decision to focus this study on severe HC was based
both on its clinical relevance, and on the accuracy of the
diagnosis. Severe HC is a rare but potentially devastating
complication of BMT, which causes pain, prolonged hospi-
talization, and significantly increases cost of trans-
plants.2,14,26–28 Although HC can be secondary to a variety
of factors (drugs, radiation, infections), HC in the BMT
setting is usually either related to the use of CY or, later
in the course of the transplant, to viral infections.2–8,14 CY
has been widely used for conditioning patients for BMT.
Methods commonly used for prophylaxis of HC in BMT
patients are intravenous hyperhydration (IVH), continuous
bladder irrigation (CBI) and, more recently Mesna.29,30
Each of these prophylaxes has side-effects: IVH can pre-
cipitate fluid overload, congestive heart failure, electrolyte
imbalances, especially when associated with CY-induced
anti-diuresis.13,30 CBI is associated with a higher incidence
of microscopic hematuria, is uncomfortable, and is very dif-
ficult to use in the pediatric population. Mesna (6 mercapto-
ethane sodium sulfonate, a sulfhydryl-containing
compound) has comparatively fewer side-effects. In our
study, we found that the incidence of severe HC progress-
ively decreased over time (trend test, P , 0.01). This
decrease, however, could not be attributed to Mesna use,
since the decline in incidence started before Mesna was
introduced, and in multiple regression analyses Mesna was
not found to have a superior effect in preventing severe HC.
Our finding is consistent with earlier clinical trials which
demonstrated no difference in efficacy of preventing HC
by various prophylactic methods.11,30 We did not observe
an increase in graft failure rate after introduction of Mesna
into our program (data not shown), although some authors
have suggested that Mesna might increase the risk of
graft failure.13
The incidence of severe HC for all types of transplant,
ie autologous, sibling donor and unrelated donors, was high
when the treatment modalities were first introduced into
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Table 4 Complications of severe hemorrhagic cystitis
Complication No. patients (%)
(n = 92)
Urinary obstruction 19 20.7
Acute renal failure with dialysis 10 10.7
Acute renal failure without dialysis 9 9.8
Hydronephrosis 9 9.8
Death-related to hemorrhagic cystitis 5 5.4
Bladder perforation 2 2.2
clinical practice, and subsequently declined. Such a pattern
is probably related to patient selection. It is known that the
incidence of RRT is directly related to aggressiveness of
the disease and to the time from diagnosis.31 It is common
practice that new treatment modalities are initially perfor-
med in patients with more aggressive diseases, and accord-
ingly associated with a higher risk of RRT. Additional risk
factors for severe HC identified from this study are use of
busulfan, presence of GVHD, and age at transplantation
(10–30 years of age compared to age under 10), consistent
with some earlier reports.14,31–33 It is unclear, however,
whether GVHD per se can manifest as HC,34 or whether
GVHD-related immunosuppressive therapies increase the
chances of opportunistic infections35 and subsequently
cause HC. Notably, patients with ALD had an unusually
high risk of severe HC (five out of 12 transplants), suggest-
ing this group of patients may have an abnormal sensitivity
to the chemotherapy. Some patients with severe HC had
positive urine cultures for viruses as previously
reported.7,36,37 CMV was also more frequently found in the
urine of patients with HC.
In summary, our study demonstrated a decreasing inci-
dence of severe HC over the past 20 years. Prophylactic
use of Mesna was not a significant factor in this decreased
incidence. Patients with certain characteristics, such as
older age, use of busulfan, CML and GVHD, have a high
risk of developing severe HC.
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